1. World Health Organization. Global tuberculosis report 2024 [Internet]. Geneva: World Health Organization; 2024 [cited 2026 May 13]. Available from: https://www.who.int/publications/i/item/9789240101531
2. World Health Organization. Global tuberculosis report 2025 [Internet]. Geneva: World Health Organization; 2025 [cited 2026 Sep 26]. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports
3. World Health Organization. WHO tuberculosis country profiles 2024 [Internet]. Geneva: World Health Organization; 2024 [cited 2026 May 13]. Available from: https://www.who.int/teams/global-tuberculosis-programme/country-profiles
4. Hoza AS, Mfinanga SG, Rodloff AC, König B. Anti-TB drug resistance in Tanga, Tanzania. Asian Pac J Trop Med. 2015;8(11):907-13. [
DOI:10.1016/j.apjtm.2015.10.014] [
PMID]
5. Kapata N, Mbulo G, Cobelens F, de Haas P, Schaap A, Mwamba P, et al. The second Zambian national tuberculosis drug resistance survey-a comparison of conventional and molecular methods. Trop Med Int Health. 2015;20(11):1492-500. [
DOI:10.1111/tmi.12581] [
PMID]
6. Ombura IP, Onyango N, Odera S, Mutua F, Nyagol J. Prevalence of drug resistance Mycobacterium tuberculosis among patients seen in Coast Provincial General Hospital, Mombasa, Kenya. PLoS One. 2016;11(10):e0163994. [
DOI:10.1371/journal.pone.0163994] [
PMID] [
PMCID]
7. Migliori GB, Dheda K, Centis R, Mwaba P, Bates M, O'Grady J, et al. Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Trop Med Int Health. 2010;15(9):1052-66. [
DOI:10.1111/j.1365-3156.2010.02581.x] [
PMID]
8. Saravanan M, Niguse S, Abdulkader M, Tsegay E, Hailekiros H, Gebrekidan A, et al. Review on emergence of drug-resistant tuberculosis (MDR & XDR-TB) and its molecular diagnosis in Ethiopia. Microb Pathog. 2018;117:237-42. [
DOI:10.1016/j.micpath.2018.02.047] [
PMID]
9. National Tuberculosis, Leprosy and Buruli Ulcer Control Programme. National Strategic Plan for Tuberculosis, Leprosy and Buruli Ulcer Control 2023-2027. Abuja: Federal Ministry of Health, Nigeria; 2023.
10. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014;2014(1):CD009593. [
DOI:10.1002/14651858.CD009593.pub3]
11. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection. 3rd ed. Geneva: World Health Organization; 2024 [cited 2026 May 13]. Available from: https://www.who.int/publications/i/item/9789240089488
12. Munir MK, Rehman S, Aasim M, Iqbal R, Saeed S. Comparison of Ziehl Neelsen microscopy with GeneXpert for detection of Mycobacterium tuberculosis. IOSR J Dent Med Sci. 2015;14(11):56-60.
13. Umair M, Siddiqui S, Farooq MA. Diagnostic accuracy of sputum microscopy in comparison with GeneXpert in pulmonary tuberculosis. Cureus. 2020;12(11):e11383. [
DOI:10.7759/cureus.11383]
14. Onekutu A, Ayom FI, Iboyi MO. Prevalence and distribution of human onchocerciasis and dermatological features in Kwande Local Government Area of Benue State, Nigeria. J Adv Med Med Res. 2018;27(3):1-10. [
DOI:10.9734/JAMMR/2018/40092]
15. Agber PM, Shabu T, Dam DP, Onah MA, Ahile JO. Assessment of the effect of anthropogenic activities on forest resources in Kwande Local Government Area, Benue State, Nigeria. Iconic Res Eng J. 2025;8(10):633-44.
16. National Bureau of Statistics (NBS), National Population Commission (NPC). Population estimates 2006-2016 [Internet]. Abuja: National Bureau of Statistics; 2016 [cited 2026 May 13]. Available from: https://nigerianstat.gov.ng/download/474
17. Araoye MO. Research methodology with statistics for health and social sciences. Ilorin: Nathadex Publishers; 2004.
18. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20(1):37-46. [
DOI:10.1177/001316446002000104]
19. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-74. [
DOI:10.2307/2529310]
20. Hussey MA, Zayaitz A. Acid-fast stain protocols [Internet]. Washington (DC): American Society for Microbiology; 2008 [cited 2026 May 13]. Available from: https://asm.org/asm/media/protocol-images/acid-fast-stain-protocols.pdf
21. Cepheid. Xpert MTB/RIF assay: package insert [Internet]. Sunnyvale (CA): Cepheid; 2020 [cited 2026 May 13]. Available from: https://www.cepheid.com/en/tests/pulmonary-testing/xpert-mtb-rif
22. World Health Organization. Tuberculosis [Internet]. Geneva: World Health Organization; 2024 [cited 2026 May 13]. Fact sheet. Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis
23. Raviglione M, Sulis G. Tuberculosis 2015: burden, challenges and strategy for control. Infect Dis Rep. 2016;8(2):6570. [
DOI:10.4081/idr.2016.6570] [
PMID]
24. Parsons LM, Somoskovi A, Gutierrez C, Lee E, Paramasivan CN, Perkins MD, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev. 2011;24(2):314-50. [
DOI:10.1128/CMR.00059-10] [
PMID] [
PMCID]
25. Opota O, Senn L, Prod'hom G, Mazza-Stalder J, Tissot F, Greub G, et al. Added value of Xpert MTB/RIF compared to sputum smear microscopy to assess tuberculosis transmission risk. Clin Microbiol Infect. 2016;22(7):613-9. [
DOI:10.1016/j.cmi.2016.04.010] [
PMID]
26. Singhal R, Myneedu VP. Microscopy as a diagnostic tool in pulmonary tuberculosis. Int J Mycobacteriol. 2015;4(1):1-6. [
DOI:10.1016/j.ijmyco.2014.12.006] [
PMID]
27. Furin J, Cox H, Pai M. Tuberculosis. Lancet. 2019;393(10181):1642-56. [
DOI:10.1016/S0140-6736(19)30308-3] [
PMID]
28. Boehme CC, Nicol MP, Nabeta P, Krapp F, Taucher-Mathis M, Fourie B, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;377(9776):1495-505. [
DOI:10.1016/S0140-6736(11)60438-8] [
PMID]
29. Fouda ME, Abdel Gwad ER, Fayed SM, Kamel MH, Ahmed SA. A study of the added value of Xpert MTB/RIF assay for assessment of pulmonary tuberculosis transmission risk. Egypt J Med Microbiol. 2019;28(3):141-8. [
DOI:10.21608/ejmm.2019.283183]
30. Ogbo FA, Ogeleka P, Okoro A, Olusanya BO, Ifegwu IK, Awosemo AO, et al. Tuberculosis burden and attributable risk factors in Nigeria, 1990-2016. Trop Med Health. 2018;46:34. [
DOI:10.1186/s41182-018-0114-9] [
PMID] [
PMCID]
31. Kolade ER, Atilola OG, Babalola TV, Komolafe OI. HIV-TB co-infection and associated risk factors among HIV positive patients at Olabisi Onabanjo University Teaching Hospital, Ogun State, South-West Nigeria. HIV AIDS Rev. 2016;15(2):69-72. [
DOI:10.1016/j.hivar.2016.03.004]
32. Mathew AO, Gbenga AO, Salami OO, Alaka-Coker AA, Idris MG, Onyeoghani N. Tuberculosis and HIV co-infection in Lagos, Nigeria. Arch Appl Sci Res. 2015;7(7):69-74.
33. Gyar SD, Dauda E, Reuben CR. Prevalence of tuberculosis in HIV/AIDS patients in Lafia. Int J Curr Microbiol Appl Sci. 2014;3(6):831-8.
34. Muhammad A, Muhammad SA. Retrospective study of HIV and tuberculosis co-infection among HIV sero-positive patients in Kano, Nigeria. ARC J Immunol Vaccines. 2018;3(2):24-30.
35. Atilola G, Randle T, Obadara T, Komolafe I, Odutolu G, Olomu J, et al. Epidemiology of HIV and tuberculosis in pregnant women in southwest Nigeria. J Infect Public Health. 2018;11(6):826-33. [
DOI:10.1016/j.jiph.2018.06.004] [
PMID]
36. Adu ME, Ezie E, Isibor CN, Jemikalajah DJ. Prevalence of Mycobacterium tuberculosis in HIV patients at ART Centre Agbor, Nigeria. Afr J Cell Pathol. 2015;4(5):62-5. [
DOI:10.5897/AJCPATH15.011]
37. Herzmann C, Sotgiu G, Bellinger O, Diel R, Gerdes S, Goetsch U, et al. Risk for latent and active tuberculosis in Germany. Infection. 2017;45:283-90. [
DOI:10.1007/s15010-016-0963-2] [
PMID] [
PMCID]
38. Sani RA, Garba SA, Oyeleke SB, Abalaka ME. Prevalence of pulmonary tuberculosis (PTB) in Minna and Suleja Niger State, Nigeria. Am J Med Med Sci. 2015;5(6):287-91.
39. Egbe K, Ike AC, Aleruchi C. Prevalence of tuberculosis and rifampicin resistance in Nasarawa State. Sci J Public Health. 2016;4(3):214-8. [
DOI:10.11648/j.sjph.20160403.18]
40. Hertz D, Schneider BE. Sex differences in tuberculosis. Semin Immunopathol. 2019;41:225-37. [
DOI:10.1007/s00281-018-0725-6] [
PMID]
41. Horton KC, MacPherson P, Houben RMGJ, White RG, Corbett EL. Sex differences in tuberculosis burden and notifications in low- and middle-income countries: a systematic review and meta-analysis. PLoS Med. 2016;13(9):e1002119. [
DOI:10.1371/journal.pmed.1002119] [
PMID]
42. Nhamoyebonde S, Leslie A. Biological differences between the sexes and susceptibility to tuberculosis. J Infect Dis. 2014;209(Suppl 3):S100-6. [
DOI:10.1093/infdis/jiu147] [
PMID]
43. Ahmad T, Zohaib MD. Prevalence of tuberculosis in Lower Dir district, Pakistan. Middle East J Sci Res. 2015;23(1):14-7.
44. Eze GU, Aduh U, Obiebi IP, Obodo KT. Profile and treatment outcomes of tuberculosis patients on DOTS in Delta State, Nigeria. J Community Med Prim Health Care. 2018;30(1):34-46.
45. Baba IA, Hıncal E. Statistical analysis of tuberculosis in Jigawa State, North-Western Nigeria. Malays J Med Biol Res. 2017;4(2):79-84. [
DOI:10.18034/mjmbr.v4i2.429]
46. Kelemuwa D, Shiferaw B, Fekadu Y. Prevalence of tuberculosis co-infection and associated factors among HIV patients attending anti-retroviral therapy at Jimma University Specialized Teaching Hospital, South West Ethiopia. J Med Physiol Biophys. 2017;29:1-12.
47. Oladimeji O, Tsoka-Gwegweni JM, Adeyinka DA, Makola L, Mitonga KH, Udoh EE, et al. Knowledge, attitude and perception of tuberculosis management among tuberculosis-infected patients in resource constraint setting: field experience from Oyo state, South-West, Nigeria. Int J Community Med Public Health. 2018;5(5):1694-706. [
DOI:10.18203/2394-6040.ijcmph20181379]
48. Bisallah CI, Rampal L, Lye MS, Mohd Sidik S, Ibrahim N, Iliyasu Z, et al. Effectiveness of health education intervention in improving knowledge, attitude, and practices regarding tuberculosis among HIV patients in General Hospital Minna, Nigeria: a randomized control trial. PLoS One. 2018;13(2):e0192276. [
DOI:10.1371/journal.pone.0192276] [
PMID] [
PMCID]
49. Hoa NP, Diwan VK, Co NV, Thorson AE. Knowledge about tuberculosis and its treatment among new pulmonary tuberculosis patients in Vietnam. Int J Tuberc Lung Dis. 2004;8(5):603-8.
50. World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2022 update [Internet]. Geneva: World Health Organization; 2022 [cited 2026 May 13]. Available from: https://www.who.int/publications/i/item/9789240048096
51. Okanurak K, Kitayaporn D, Akarasewi P. Factors contributing to tuberculosis treatment success. Int J Tuberc Lung Dis. 2008;12(10):1160-5.
52. Narasimhan P, Wood J, MacIntyre CR, Mathai D. Risk factors for tuberculosis. Pulm Med. 2013;2013:828939. [
DOI:10.1155/2013/828939] [
PMID] [
PMCID]
53. Oni T, Gideon HP, Bangani N, Tsekela R, Seldon R, Wood K, et al. Smoking, BCG and employment as tuberculosis risk factors in a high TB burden setting. PLoS One. 2012;7(10):e47072. [
DOI:10.1371/journal.pone.0047072] [
PMID] [
PMCID]
54. Domínguez J, Boettger EC, Cirillo D, Cobelens F, Eisenach KD, Gagneux S, et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis. 2016;20(1):24-42. [
DOI:10.5588/ijtld.15.0221] [
PMID]
55. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. Geneva: World Health Organization; 2021.
56. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005-15. [
DOI:10.1056/NEJMoa0907847] [
PMID]
57. Theron G, Venter R, Smith L, Esmail A, Randall P, Sood V, et al. False-positive Xpert MTB/RIF results in retested patients. J Clin Microbiol. 2018;56(4):e01696-17. [
DOI:10.1128/JCM.01696-17] [
PMID] [
PMCID]
58. Lawn SD, Nicol MP. Xpert MTB/RIF assay: development, evaluation and implementation. Future Microbiol. 2011;6(9):1067-82. [
DOI:10.2217/fmb.11.84] [
PMID] [
PMCID]